Whisper it, but we may finally be seeing the IPO window reopening in 2026. | Whisper it, but we may finally be seeing the IPO window reopening in 2026.

By Kane Wu and Andrew Silver HONG KONG/SHANGHAI, Feb 13 (Reuters) - Global drugmakers are stepping up their search for China‑developed experimental medicines as they cut costs ahead of patent ...

2026 could be a big year for this company.

The latest firm to top up its venture capital coffers is Austin, Texas-based Santé Ventures, which on Monday announced its ...

AI-assisted drug discovery isn’t just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI ...

Orna Therapeutics, which engineers immune cells inside the body, will fold into one of the world’s largest drugmakers. The post Eli Lilly snaps up Watertown biotech in $2.4 billion deal appeared first ...

In an era of escalating biological threats, from weaponized pathogens to evolving viruses like Mpox, small U.S. biotechs are stepping up to bolster military readiness and national security.

Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...

The companies Aktis Oncology, Alumis, and Parabilis Medicines bagged the biggest biotech funding rounds overall in January ...

A group of European venture capital firms is banding together to try to improve the funding landscape for biotech startups.

Eli Lilly will acquire Orna Therapeutics for up to $2.4 billion to gain access to the Watertown biotech's circular RNA ...

Capcom and biotech art group LOM BABY bring Resident Evil’s T-virus to Shibuya PARCO, explaining the exhibit, safety claims, and real biotech context ...